In a previous prospective study, including ER+ early-stage breast cancer patients in whom the benefit of adjuvant chemotherapy was considered disputable based on the clinicopathological characteristics, we evaluated the clinical impact of 70-Gene Signature (70-GS) use [13]. The gene discussed is ESR1; the disease is breast cancer.